
Arachidonic-acid identity-and-context orientation. Hydrogens are omitted; the plate is not a crystallographic conformation and does not show release, oxidation, eicosanoid synthesis, inflammation, concentration, or treatment effect.
Scientific media record3 verified identifiers
- Subject
- Arachidonic Acidbiological-process
- Review
- Editorial review completeIdentifiers authority-verified · Accessibility validated · · arachidonic-acid|arachidonic-acid-mechanism-v1.webp
- Digital source
- Trained-algorithmic mediaCreated with a trained generative algorithm and reviewed by WikiBiome for subject identity, scientific framing, identifiers, provenance, and accessibility.
- Scientific basis
- Arachidonic Acid — PubChemArachidonic acid — ChEBI
- License
- CC BY-SA 4.0Created
Arachidonic acid (AA) is a 20-carbon omega-6 polyunsaturated fatty acid (20:4n-6) that serves as the primary substrate for prostaglandin and leukotriene synthesis via COX-2 and 5-LOX pathways.
It is the dominant pro-inflammatory lipid mediator—and its balance with anti-inflammatory omega-3 fatty acids (EPA/DHA) determines the inflammatory tone across multiple disease signatures.
Evidence map4 cited passagesInspect provenance +
COX-2/NF-kB axis: Metal-driven NF-kB activation upregulates COX-2, increasing arachidonic acid conversion to pro-inflammatory prostaglandin E2 (PGE2)—the same pathway activated by microbial LPS via TLR4.
NSAIDs and microbiome: NSAIDs (COX inhibitors blocking AA metabolism) cause gut microbiome disruption and intestinal injury, paradoxically increasing dysbiosis while reducing inflammation.
Endometriosis metabolomics: Altered arachidonic acid levels in fecal metabolomics of endometriosis models.
Diabetic ED: Fatty acid profiles including AA altered in diabetic erectile dysfunction.
Microbiome Connection#
COX-2/NF-kB axis: Metal-driven NF-kB activation upregulates COX-2, increasing arachidonic acid conversion to pro-inflammatory prostaglandin E2 (PGE2)—the same pathway activated by microbial LPS via TLR4.[1]Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic InflammationFabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. · 2019Open reference 1 ↓
NSAIDs and microbiome: NSAIDs (COX inhibitors blocking AA metabolism) cause Gut Microbiome disruption and intestinal injury, paradoxically increasing Dysbiosis while reducing Metal-Driven Inflammation.[1]Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic InflammationFabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. · 2019Open reference 1 ↓
Endometriosis metabolomics: Altered arachidonic acid levels in fecal metabolomics of endometriosis models.[2]Ni 2020 — Fecal Metabolomics and Gut Microbiota Correlation in Endometriosis MiceZhexin Ni, Shuai Sun, Yanli Bi et al. · 2020Open reference 2 ↓ Diabetic ED: Fatty acid profiles including AA altered in diabetic erectile dysfunction.[3]Ben Khedher 2017 — Disturbed Fatty Acids Metabolism in Diabetic Erectile DysfunctionMohamed Raâfet Ben Khedher, Houda Bouhajja, Samia Haj Ahmed et al. · 2017Open reference 3 ↓
Resolution Pathway#
Arachidonic acid is also the precursor for lipoxins—pro-resolving mediators that actively terminate inflammation. The balance between pro-inflammatory (prostaglandins) and pro-resolving (lipoxins) AA metabolites depends on the enzymatic context, which metals can disrupt.
Cross-References#
- inflammation—AA/COX-2 as pro-inflammatory pathway
- Omega-3 Fatty Acids (EPA/DHA)—anti-inflammatory counterbalance to AA
- Lipid Metabolism—broader lipid context
- Lipid Peroxidation—AA as substrate for oxidative damage
- NF-kB Signaling Pathway—NF-kB drives COX-2/AA pathway
References 5
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Fabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. (2019). Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic Inflammation. Facta Universitatis Series Medicine and Biology.
- 2
Zhexin Ni, Shuai Sun, Yanli Bi et al. (2020). Ni 2020 — Fecal Metabolomics and Gut Microbiota Correlation in Endometriosis Mice. American Journal of Reproductive Immunology.
- 3
Mohamed Raâfet Ben Khedher, Houda Bouhajja, Samia Haj Ahmed et al. (2017). Ben Khedher 2017 — Disturbed Fatty Acids Metabolism in Diabetic Erectile Dysfunction. Lipids in Health and Disease.
- 4
Xinyun Bi, Fanghong Li, Shanshan Liu et al. (2017). Bi 2017 — Omega-3 Polyunsaturated Fatty Acids Ameliorate Type 1 Diabetes and Autoimmunity. Journal of Clinical Investigation.
- 5
Martin DA, Bolling BW (2015). A Review of the Efficacy of Dietary Polyphenols in Experimental Models of Inflammatory Bowel Diseases. Food & Function.
Article network
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Published page changes
This record shows only material changes published on this page, including changes to its content, evidence, conclusions, or author context. Internal processes and discussion activity are excluded. Pending, declined, and withdrawn proposals remain private.
- published revision
Created “Arachidonic Acid”: Arachidonic acid (AA) is a 20-carbon omega-6 polyunsaturated fatty acid (20:4n-6) that serves as the primary substrate for prostaglandin and leukotriene synthesis via COX-2 and 5-LOX pathways. It is…
Created “Arachidonic Acid”: Arachidonic acid (AA) is a 20-carbon omega-6 polyunsaturated fatty acid (20:4n-6) that serves as the primary substrate for prostaglandin and leukotriene synthesis via COX-2 and 5-LOX pathways. It is… Published sections: Overview; Microbiome Connection; Resolution Pathway; Cross-References. · WikiBiome Deploy Bot · +43 −0
Inspect exact Git diff ↗

